查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198490

支架市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Stents Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，支架市場預計將以 5.3% 的複合年增長率增長。

COVID-19 的早期影響受到了世界各地取消擇期手術（包括外科手術）的負面影響。 例如，世衛組織於 2020 年 5 月在 155 個國家進行的為期三週的調查發現，包括各種心血管疾病在內的各種慢性病的預防和治療服務受到嚴重阻礙，慢性病患者經歷了 COVID-19。有人指出，19相關的病情加重和死亡的風險很高。 一項重要發現是，超過一半 (53%) 的受調查國家部分或完全暫停了高血壓護理服務，31% 的國家暫停了心血管急救服務，這影響了市場增長。 然而，隨著全球外科手術的恢復，它開始在市場上受到關注。 根據歐盟統計局的數據，2020 年德國進行了近 38,900 例心臟搭橋手術。 預計在預測期內，心臟手術和支架植入術的數量將增加，這將對市場增長產生積極影響。

預計心臟相關疾病的高負擔會增加血管成形術的數量，從而在預測期內促進市場增長。 此外，慢性病的增加、老年人口的增加以及支架開發的技術進步都對市場增長產生了積極影響。

根據《世界人口展望》，2022 年 65 歲及以上人口的比例估計為 9.7，到 2030 年將達到 11.7。 心房顫動是老年人主要的心律失常，可通過冠狀動脈支架置入術治療。 預計老年人口的快速增長將在預測期內推動市場增長。

此外，據 WSO 稱，每年診斷出大約 500 萬新的心房顫動和撲動病例。 所有年齡和性別的房顫發病率為 470 萬，預計到 2022 年患病率將達到 6000 萬。 預計在預測期內，房顫的高負擔將擴大支架市場。

在過去十年中，慢性病的患病率有所增加。 據 AHA 稱，到 2021 年，外周動脈疾病 (PAD) 將影響全球 2 億多人，並且與高死亡率和發病率有關。 隨著世界人口老齡化，PAD 在預測期內可能會變得越來越普遍。 統計數據顯示，PAD 患者的數量正在以更快的速度增長，這最終推動了支架市場。

此外，根據 AHA 發表的科學研究，到 2021 年，全球將有超過 2.3 億人受到外周下肢動脈疾病 (PAD) 的影響，並帶來一些不利的臨床後果（冠心病、中風等心血管疾病和肢體結果，如截肢情況）。 由於 PAD 的治療需要支架，預計 PAD 發病率的增加最終將在預測期內推動支架市場。

此外，技術進步以及主要參與者的產品批准、合作夥伴關係和收購的增加正在推動市場的增長。 例如，2022 年 3 月，全球心血管技術公司 Cordis 的 Smart Radianz 血管支架系統獲得 FDA 批准，這是一種專門為外周橈動脈手術設計的自擴張支架。 預計此類技術進步將在全球範圍內增加支架在有效根治性治療中的應用。

因此，由於上述因素，該市場有望在預測期內增長。 然而，嚴格的支架審批流程和頻繁的產品召回可能會阻礙市場增長。

支架市場趨勢

藥物洗脫支架部分預計在預測期內增長

藥物洗脫支架是置入堵塞和病變的外周動脈和冠狀動脈內，緩慢釋放藥物抑制細胞增殖的支架，用於外周動脈和冠狀動脈。

由於心髒病的增加，全球對冠狀動脈支架的需求不斷增加。 根據疾病預防控制中心的數據，到 2020 年，美國將有大約 2010 萬 20 歲及以上的成年人患有冠心病 (CAD)。 它還指出，冠心病是美國最常見的心髒病類型。 人群中心髒病的高患病率已經收穫了對支架的需求。

技術進步、產品批准的增加以及主要參與者的合作夥伴關係和收購正在推動這一細分市場的增長。 例如，2022 年 1 月，Cook Medical 因其用於膝蓋以下的新型藥物洗脫支架 (BTK) 獲得了美國 FDA 的突破性設備指定。 這種新型支架用於治療威脅四肢的持續性缺血患者。 2021年8月，賽諾美在愛爾蘭推出藥物洗脫支架HT Supreme。 預計此類發布將在預測期內促進該細分市場的增長。

北美有望在預測期內主導支架市場

北美的特點是慢性病發病率上升、人口老齡化、行業參與者在該地區的強大影響力、出色的醫療保健基礎設施以及人與行業之間在該地區可用技術方面的關係。預計消費者意識提高等因素壟斷市場。

此外，人口老齡化的加劇和與生活方式相關的疾病發病率的上升對所調查市場的增長產生了積極影響。 例如，加拿大統計局的 2021 年人口普查顯示，到 2021 年，65 歲及以上的人口將約為 7,021,430 人，其中男性 3,224,680 人，女性 3,796,750 人。 老年人口易患嚴重的心血管疾病，需要支架治療。 因此，該地區老齡化人口的快速增加可能會增加市場增長。

由於用於不同條件的支架的創新，預計主要市場參與者和機構參與該地區的研發工作將促進市場增長。 例如，2021 年 10 月，波士頓科學公司將在拉斯維加斯舉行的血管介入進展 (VIVA) 會議上的臨床試驗演示中展示 Eluvia 藥物洗脫血管支架系統的積極臨床試驗結果。底部。 來自 EMINENT 試驗的數據表明，Elvia 支架在治療外周動脈疾病（PAD）和股淺動脈（SFA）病變長達 210 毫米的患者方面優於自擴張裸金屬支架（BMS）。增加。 該研究招募了 775 名患者，使其成為迄今為止最大的藥物洗脫支架治療外周動脈疾病的隨機試驗。 此類臨床試驗有望促進支架在該地區的使用。

因此，由於上述因素，北美市場有望擴大。

支架市場競爭對手分析

由於公司在全球和區域開展業務，因此支架市場在本質上是分散的。 競爭格局包括對少數具有市場份額的知名國際和本地公司的分析。 一些主要的市場參與者是波士頓科學公司、雅培、美敦力、B. Brown、Becton、Dickinson and Company、Microport Scientific Inc.、Biotronik、Cook Group、Allium Medical Solutions Inc.、Elixir Medical、Terumo Corporation 等。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性病患病率增加
    • 老年人口增加
    • 支架開發的技術進步
  • 市場製約因素
    • 支架的嚴格審批流程
    • 產品回收率高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按產品分類
    • 冠狀動脈支架
      • 藥物洗脫支架
      • 裸金屬冠狀動脈支架
      • 生物可吸收支架
    • 外圍設備支架
      • 髂支架
      • 股骨/膕窩支架
      • 腎臟和相關支架
      • 頸動脈支架
    • 支架植入物
  • 按材料
    • 金屬生物材料
    • 高分子生物材料
    • 天然生物材料
  • 按地區細分
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Boston Scientific Corporation
    • Abbott
    • Medtronic
    • B. Braun SE
    • Becton, Dickinson and Company
    • Microport Scientific Corporation
    • Biotronik
    • Cook Group
    • Allium Medical Solutions Ltd
    • Elixir Medical
    • Terumo Corporation

第7章 市場機會與今後動向

簡介目錄
Product Code: 67149

The stents market is expected to register a CAGR of 5.3% during the forecast period.

The impact of COVID-19 in its initial phase was adverse due to the cancellations of elective procedures, including surgeries worldwide. For instance, a WHO survey conducted for 155 countries for three weeks in May 2020 indicated that the prevention and treatment services of various chronic diseases, including various cardiovascular disorders, had been severely disrupted, and people with chronic conditions were at a higher risk of severe COVID-19-related illness and death. The key finding suggested that more than half (53%) of the countries surveyed had partially or wholly disrupted services for hypertension treatment and 31% for cardiovascular emergencies, which impacted the growth of the market. However, the market started to gain traction owing to the resumption of surgical procedures worldwide. According to Eurostat, nearly 38,900 heart bypasses were conducted in Germany in 2020. The number of cardiac surgical procedures and stent implantations is projected to grow during the forecast period, positively impacting the growth of the market.

The high burden of heart-related diseases is expected to increase the number of angioplasties, thereby augmenting market growth during the forecast period. In addition, the increasing prevalence of chronic diseases, the growing geriatric population, and technological advancements in stent development are actively affecting the growth of the market.

According to the World Population Prospects, the percentage of the population aged 65 and over was 9.7 in 2022, and it is estimated to reach 11.7 in 2030. Atrial fibrillation is a major heart rhythm disorder among older people, which leads to coronary stent implantation for treatment. The surge in the geriatric population is projected to propel the growth of the market during the forecast period.

Additionally, as per the WSO, almost 5 million new cases of atrial fibrillation and flutter are diagnosed each year. The incidence of atrial fibrillation in all ages and sexes was 4.7 million, and the prevalence was expected to reach 60 million in 2022. The high burden of atrial fibrillation is projected to augment the stents market during the forecast period.

The prevalence of chronic illnesses has increased over the decade. According to the AHA, peripheral artery disease (PAD) affected more than 200 million people worldwide and was associated with high mortality and morbidity in 2021. With the aging global population, PAD may likely become increasingly common during the forecast period. Statistics show that the number of PAD patients is increasing at a faster pace, which is ultimately driving the market for stents.

Additionally, as per a scientific study published by the AHA, lower extremity peripheral artery disease (PAD) affected more than 230 million individuals worldwide in 2021, and it is linked to an elevated risk of several unfavorable clinical outcomes (including cardiovascular diseases like coronary heart disease and stroke and limb outcomes like amputee status). Since the treatment of PAD requires stents, the increased incidence of PAD is ultimately projected to boost the stents market during the forecast period.

Furthermore, the advancements in technology and the increasing number of product approvals, partnerships, and acquisitions by key players are helping the market grow. For instance, in March 2022, Cordis, a global cardiovascular technology company, received FDA approval for its Smart Radianz Vascular Stent System, a self-expanding stent designed explicitly for radial peripheral procedures. Such technological advancements are projected to boost the utility of stents worldwide for effective underlying treatments.

Therefore, owing to the abovementioned factors, it is anticipated that the market studied will witness growth over the forecast period. However, a stringent approval process for stents and high product recalls are likely to impede the growth of the market.

Stents Market Trends

The Drug-eluting Stents Segment is Expected to Witness Growth During the Forecast period

A drug-eluting stent is a peripheral or coronary stent inserted into clogged, diseased peripheral or coronary arteries, slowly releasing a drug to block cell proliferation.

Due to the increase in the number of cardiac disorders, there is an increased demand for coronary stents worldwide. According to the CDC, about 20.1 million adults aged 20 and older had coronary heart disease (CAD) in the United States in 2020. It also stated that coronary heart disease is the most common type of heart disease in the United States. The high prevalence of cardiac diseases among the population reaped the demand for stents.

The advancements in technology, increasing product approvals, and partnerships and acquisitions by key players are driving the growth of the segment. For instance, in January 2022, Cook Medical received a breakthrough device designation from the US FDA on a new drug-eluting stent for below the knee (BTK). This novel stent is used to treat individuals with limb-threatening persistent ischemia. In August 2021, Sinomed launched its HT Supreme drug-eluting stent in Ireland. Such launches are projected to augment the growth of the segment during the forecast period.

North America is Expected to Dominate the Stents Market During the Forecast Period

North America is expected to dominate the market owing to factors such as the rising incidence of chronic diseases, the growing geriatric population, the strong presence of industry players in the region, better healthcare infrastructure, and increased awareness among people and healthcare industry stakeholders about available technologies in the region.

In addition, the rise in the geriatric population and the increase in the incidence of lifestyle diseases are actively affecting the growth of the market studied. For instance, according to the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above in 2021, out of which 3,224,680 were males, and 3,796,750 were females. The geriatric population is prone to critical cardiovascular diseases that require stents for treatment. Thus, the surge in the geriatric population in the region is likely to augment the growth of the market.

The engagement of key market players and institutions in research and development in the region for innovation in the stents used for different conditions is projected to augment the growth of the market. For instance, in October 2021, Boston Scientific Corporation presented positive clinical trial results for the Eluvia drug-eluting vascular stent system during a clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. According to the data from the EMINENT trial, the Eluvia stent outperformed self-expanding bare metal stents (BMS) for the treatment of patients with peripheral arterial disease (PAD) and superficial femoral artery (SFA) lesions up to 210 mm in length. The study included 775 patients, making it one of the biggest drug-eluting stent randomized trials for peripheral artery disease treatment to date. Such clinical trials are anticipated to fuel the use of stents in the region.

Therefore, owing to the abovementioned factors, the market studied is anticipated to grow in the North American region.

Stents Market Competitor Analysis

The stents market is fragmented in nature due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some key market players are Boston Scientific Corporation, Abbott, Medtronic, B. Braun, Becton, Dickinson and Company, Microport Scientific Corporation, Biotronik, Cook Group, Allium Medical Solutions Ltd, Elixir Medical, and Terumo Corporation, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases
    • 4.2.2 Increasing Geriatric Population
    • 4.2.3 Technological Advancements in Stent Development
  • 4.3 Market Restraints
    • 4.3.1 Stringent Approval Process for Stents
    • 4.3.2 High Product Recalls
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Coronary Stents
      • 5.1.1.1 Drug-eluting Stents
      • 5.1.1.2 Bare-metal coronary Stents
      • 5.1.1.3 Bioabsorbable Stents
    • 5.1.2 Peripheral stents
      • 5.1.2.1 Iliac Stents
      • 5.1.2.2 Femoral-popliteal Stents
      • 5.1.2.3 Renal and Related Stents
      • 5.1.2.4 Carotid Stents
    • 5.1.3 Stent Implants
  • 5.2 By Material
    • 5.2.1 Metallic biomaterials
    • 5.2.2 Polymeric biomaterials
    • 5.2.3 Natural biomaterials
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Abbott
    • 6.1.3 Medtronic
    • 6.1.4 B. Braun SE
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Microport Scientific Corporation
    • 6.1.7 Biotronik
    • 6.1.8 Cook Group
    • 6.1.9 Allium Medical Solutions Ltd
    • 6.1.10 Elixir Medical
    • 6.1.11 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS